Skip to main content
Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

Fig. 1

Chest computed tomography (CT) and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT. Imaging findings during the patient’s course (a, b, c, and d) at baseline (before chemotherapy), (e, f, g, and h) after chemoradiotherapy and before durvalumab consolidation therapy, (i, j, k, l, and m) after the seventh round of durvalumab, and (n, o, p, q, and r) after the ten cycles of pembrolizumab. a and b CT showing right upper lobe and hilum involvement at the time of diagnosis (May 2018). e and f CT showing the response to chemoradiotherapy (August 2018). k and l CT showing progressive disease during durvalumab therapy (November 2018). New metastatic nodules were visible in the left lower lobe (k, arrow) and the left psoas (l, arrow). m PET-CT showed FDG accumulation in the left psoas and the abdominal lymph node (arrows) (November 2018). n, o, p, q, and r Both primary and metastatic lesions were dramatically improved by pembrolizumab treatment

Back to article page